Scynexis completes patient enrollment for women’s health phase 3 study
Jersey City-based Scynexis Inc., a biotechnology company delivering therapies for difficult-to-treat and often life-threatening infections, said Thursday it completed patient enrollment, ahead of schedule, in its global Phase 3 VANISH-306 study to evaluate the safety and efficacy of oral ibrexafungerp as a treatment for women with vulvovaginal candidiasis (VVC), commonly referred to as vaginal yeast infection.
Woman of the Week Podcast
Believing in the power of one, Kinnari Patel’s passion around rare disease is leading to unique development programs and awareness campaigns; she is equally passionate about sharing her learnings on the way to the C-suite as a mentor and sponsor.
Immunomedics Q&A: using ADCs to tackle unmet needs in breast cancer
Immunomedics has developed an ADC called sacituzumab govitecan, which directly delivers chemotherapy SN-38 to TNBC tumours, which highly express Trop-2 and represents an unmet need within a highly treated cancer type. The company’s chief commercial officer Brendan Delaney explains the drug’s efficacious mechanism of action in this tumour type, as well as noting its success to date, particularly in tolerability and how Immunomedics is advancing the ADC in other Trop-2-expressing tumours.
Adverum gains on Phase I data showing efficacy for wet AMD gene therapy
Updated interim data for Adverum’s intravitreal wet age-related macular degeneration gene therapy bolstered the company’s case that the product could compete with less convenient subretinal gene therapies for the indication.
Improving Efficacy of Colorectal Cancer Treatments with Ulf Jungnelius MD Isofol Medical
Ulf Jungnelius MD, CEO, Isofol Medical discusses the increasing incidence of colorectal cancer as a global issue and the current challenges in treating this devastating disease. Dr. Jungnelius also talks about the company’s drug candidate, arfolitixorin, currently being studied in a global Phase 3 clinical trial with the aim to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer.
Trial Triumphs, Takeover Talk Boost Reata Pharmaceuticals
Warren Huff, Reata’s president and CEO, discussed the clinical progress of omaveloxolone and bardoxolone, as well as the company’s approach to drug development, before the stock surge in an exclusive interview with GEN Edge during the recent J.P. Morgan conference in San Francisco . . .
A Potential Cure for Hepatitis B
Dr. Lawrence Blatt, CEO, Aligos Therapeutics, discusses his company’s research around antisense oligonucleotides as potential therapies for chronic hepatitis B and other diseases of the liver. Despite an available vaccine, the incidence of chronic hepatitis B (HBV) remains high — the largest prevalence of any chronic virus that causes morbidity and mortality — in some regions.
Step Aside, CRISPR: RNA Editing is Taking Off
Thorsten Stafforst found his big break at the worst possible time. In 2012, his team at the University of Tübingen in Germany discovered that by linking enzymes to engineered strands of RNA, they could change the sequences of messenger RNA molecules in cells. In essence, they could rewrite the genome’s instructions en route to making proteins.
